Evaluation of Mitochondrial Function on Pyruvate Dehydrogenase Complex Deficient Patient-derived Cell Lines.

arginine energy metabolism mitochondrial bioenergetics pyruvate dehydrogenase complex pyruvate dehydrogenase complex deficiency thiamine

Journal

Endocrine, metabolic & immune disorders drug targets
ISSN: 2212-3873
Titre abrégé: Endocr Metab Immune Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269157

Informations de publication

Date de publication:
11 Oct 2023
Historique:
received: 31 08 2023
accepted: 09 09 2023
medline: 20 10 2023
pubmed: 20 10 2023
entrez: 20 10 2023
Statut: aheadofprint

Résumé

Pyruvate Dehydrogenase Complex (PDC) is a pivotal gatekeeper between cytosolic glycolysis and mitochondrial oxidative phosphorylation, playing important role in aerobic energy metabolism. Most PDC deficiency, cases being caused by mutations in PDHA1 encoding the α subunit of the rate-limiting E1 enzyme, which is characterized by abnormal phenotypes caused by energy deprivation at peripheral/central nervous systems and muscular tissues. This study aims to evaluate the potential therapeutic effect of arginine and thiamine in ameliorating mitochondrial function in patient-derived cultured cells. PDC-deficient cell lines, carrying three different PDHA1 variants, were cultured in the absence and presence of arginine and/or thiamine at therapeutical levels, 4 mM and 100 μM, respectively. Mitochondrial bioenergetics profile was evaluated using the Seahorse extracellular flux analyzer. In physiological conditions, control cells presented standard values for all parameters evaluating the mitochondrial function, no differences being observed after supplementation of culture medium with therapeutic levels of arginine and/or thiamine. However, PDC-PDHA1 deficient cell lines consumed less oxygen than the control cells, but arginine and thiamine supplementation increased the basal respiration for values similar or higher than the control cell line. Moreover, arginine and thiamine treatment highlighted an inefficient oxidative phosphorylation carried out by PDC-deficient cell lines. Finally, this treatment showed an increased oxygen consumption by enzymes other than those in the respiratory chain, thus proving the dependence of these mutant cell lines on cytosolic sources for ATP production, namely glycolysis. This study showed that arginine and thiamine, at therapeutical levels, increase the basal oxygen consumption rate of PDC-deficient cell lines, as well as their ATP-linked respiration. This parameter measures the capacity of the cell to meet its energetic demands and, therefore, its increase reveals a higher electron flow through the respiratory chain, which is coupled to elevated oxidative phosphorylation, thus indicating an overall increased robustness in mitochondrial- related bioenergetics.

Identifiants

pubmed: 37861030
pii: EMIDDT-EPUB-135107
doi: 10.2174/0118715303280072231004082458
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Hana Pavlú-Pereira (H)

Universidade de Lisboa iMed.ULisboa - Instituto de Investigação do Medicamento, Faculdade de Farmácia Lisbon Portugal.

Cristina Florindo (C)

Universidade de Lisboa iMed.ULisboa - Instituto de Investigação do Medicamento, Faculdade de Farmácia Lisbon Portugal.

Filipa Carvalho (F)

Universidade de Lisboa IMM Instituto de Medicina Molecular, Faculdade de Medicina Lisbon Portugal.

Isabel Tavares de Almeida (I)

Universidade de Lisboa Laboratory of Metabolism and Genetics, Department of Pharmaceutical Sciences and Medicines, Faculty of Pharmacy Lisbon Portugal.

Joao Vicente (J)

Universidade Nova de Lisboa Instituto de Tecnologia Química e Biológica António Xavier Lisbon Portugal.

Vanessa Morais (V)

Universidade de Lisboa IMM Instituto de Medicina Molecular, Faculdade de Medicina Lisbon Portugal.

Isabel Rivera (I)

Universidade de Lisboa iMed.ULisboa - Instituto de Investigação do Medicamento, Faculdade de Farmácia Lisbon Portugal.

Classifications MeSH